Index

Note: Page numbers of article titles are in **boldface** type.

A
Abscess(es)
  liver
    amebic
      jaundice due to, 758
      in travelers, 764–765
      travel-associated, 678–679
Accidental hypothermia, 714–715
Acclimatization
  to cold temperatures, 718–719
Africa
  rabies in
    epidemiology of, 741–742
Age
  as factor in involution of thymus, 617–619
  as factor in travel trends, 794
Allogeneic hematopoietic cell transplantation
  age-related involution of thymus and bone marrow results in,
    617–619
Altitude-related disorders, 718
Amebic liver abscess
  jaundice due to, 758
  in travelers, 764–765
America(s)
  rabies in
    epidemiology of, 741–742
American trypanosomiasis
  serology for, 814
AMS, 719
Anopheles mosquitoes
  behavior, diseases spread by, and prevention of bites by, 657
Antibiotics
  in TD prevention, 699–700
Antibody(ies)
  in depleting lymphocytes or interfere with cell function, 615–616
  in modulation of immune response, 616–617
Antigen-recognizing T-cell receptor
  intracellular signal transduction from
    inhibitors of, 613–614
Antiretroviral therapy
  for HIV
    immune reconstitution under, 619
Antisecretory drugs
  for TD, 696–697
Arboviral infection
  travel-associated, 687–688
Ascariasis
  jaundice due to, 760
  in travelers, 772–773
Asia
  rabies in
    epidemiology of, 741–742
Atovaquone/proguanil
  in malaria prevention in travelers, 642, 646
Australia
  rabies in
    epidemiology of, 741–742
Azathioprine
  in destroying dividing cells, 614–615
Azithromycin
  for TD, 698

B

**Babesia** spp.
  serology for, 812
Babesiosis
  causes of, 763
  clinical features of, 763–764
  epidemiology of, 763
  jaundice due to, 758
Behavioral interventions
  in malaria prevention in travelers, 640
Biochemistry tests
  in travelers with tropical diseases, 805
Bismuth subsalicylate
  for TD, 697
Bite(s)
  insect. See Insect bites
Biting midges
  behavior, diseases spread by, and prevention of bites by, 661
Blackflies
  behavior, diseases spread by, and prevention of bites by, 660
Blood-borne pathogens
  in mass gatherings
    detection of, 730
Blood specimens
  for tropical infections diagnosis, 805–806
Bone marrow
  results in incomplete immune reconstitution, 617–619
Bone marrow biopsy
  for tropical infections diagnosis, 809
Cardiac disease
  travelers with
    malaria prevention in, 651

Cell(s)
  dividing
    destroying of
      immunosuppressive drugs in, 614–615
  function
    antibodies interfering with, 615–616

Central nervous system (CNS) samples
  for tropical infections diagnosis, 807

Cerebral edema
  high-altitude, 719–720

Chagas disease
  serology for, 814

Chemoprophylaxis
  in malaria prevention in travelers, 640–648

Chigger mites
  behavior, diseases spread by, and prevention of bites by, 663

Children
  visiting foreign countries
    pretravel health counseling related to, 628

Children travelers, 629–630

Chloroquine
  in malaria prevention in travelers, 642

Cholera
  vaccine for
    recommended for risk during travel, 602

Chronic diseases
  travelers with
    malaria prevention in, 652–653

Clonal proliferation
  as central event in mounting effective immune response, 610–611

Clonorchiasis/opisthorchiasis
  jaundice due to, 759
  in travelers, 769–770

CNS. See Central nervous system (CNS)

Coils
  in insect bite prevention, 668–669

Cold-related disorders, 714–720
  accidental hypothermia, 714–715
  acclimatization, 718–719
  altitude-related disorders, 718
  AMS, 719
  cold water immersion, 715–716
  frostbite, 716–718
  frostnip, 716
  HACE, 719–720
  HAPE, 720

Clonorchiasis/opisthorchiasis
  jaundice due to, 759
  in travelers, 769–770

CNS. See Central nervous system (CNS)
Cold-related (continued)
  NFCI, 718
Cold water immersion, 715–716
Cramp(s)
  heat, 714
  muscle
    exercise-associated, 714
Culex mosquitoes
  behavior, diseases spread by, and prevention of bites by, 659
Cutaneous larva migrans, 683–684
Cyclophosphamide
  in destroying dividing cells, 614–615
Cyclosporin A
  in inhibition of intracellular signal transduction from antigen-recognizing T-cell receptor, 613–614

D
Deer flies
  behavior, diseases spread by, and prevention of bites by, 661
DEET
  in insect bite prevention, 666
Diarrhea
  traveler’s, 691–706, 804. See also Traveler’s diarrhea (TD)
Diphtheria
  vaccine for, 596
Doxycycline
  in malaria prevention in travelers, 643, 647
Dukoral
  in TD prevention, 700–701

E
Echinococcosis
  causes of, 770
  clinical presentation of, 771–772
  epidemiology of, 770–771
  jaundice due to, 760
  in travelers, 770–772
Edema
  cerebral
    high-altitude, 719–720
  heat, 713–714
  pulmonary
    high-altitude, 720
Encephalitis
  Japanese
    vaccine for
      recommended for risk during travel, 603–604
  tick-borne
    vaccine for
      recommended for risk during travel, 604–605
Endemic infectious diseases of local importance
in mass gatherings
detection of, 730–731

Entamoeba histolytica
serology for, 812

Environment(s)

extreme, 707–723
cold-related disorder, 714–720
heat-related disorders, 707–714

Environmental hazards, 707–723
cold-related disorders, 714–720
heat-related disorders, 707–714

Eosinophil(s)
biology and function of, 781–782

Eosinophil count
ranges of, 782–783
in returning traveler, 781

Eosinophilia
causes of, 782–783
in immigrants
rates and associations of, 783
in returning traveler, 781–789
causes of
helminth infections, 788
parasitic, 782–786
diagnostic issues, 786–787
screening algorithms for asymptomatic or paucisymptomatic patients, 787
in travelers
laboratory investigations and diagnosis of, 804
rates and associations of, 783

Epilepsy
travelers with
malaria prevention in, 652

Europe
rabies in
epidemiology of, 741–742

Everolimus
in inhibition of intracellular signal transduction from antigen-recognizing T-cell receptor, 613–614

Exercise-associated muscle cramps, 714
Exertional heat stroke, 710

F

Fascioliasis
jaundice due to, 759
serology for, 812
in travelers, 768–769

Fever
in travelers
laboratory investigations and diagnosis of, 804
Filaria
  serology for, 813
Fleas
  behavior, diseases spread by, and prevention of bites by, 663
Flies
  behavior, diseases spread by, and prevention of bites by, 660–662. See also specific types of flies
Fluid and electrolytes
  in heat replacement, 711–712
  for TD, 696
Fluoroquinolones
  for TD, 698
Food-borne diseases
  in mass gatherings
    detection of, 729–730
Food hygiene
  in TD prevention, 699
Freezing cold injury, 716–718
Frostbite, 716–718
Frostnip, 716

G
Gastrointestinal samples
  for tropical infections diagnosis, 807–808
Glucocorticoid(s)
  how they work, 612–613

H
HACE. See High-altitude cerebral edema (HACE)
HAPE. See High-altitude pulmonary edema (HAPE)
Hard ticks
  behavior, diseases spread by, and prevention of bites by, 663
Health-related counseling
  pretravel
    for VFRs, 627–628
Health-related problems
  travel-associated morbidity associated with, 798–799
Heat
  acclimatization to, 711
  injuries caused by, 709–710
Heat balance, 707–708
Heat cramps, 714
Heat edema, 713–714
Heat-related disorders, 707–714
  clinical presentations of, 710
  exertional, 710
  heat cramps, 714
  heat edema, 713–714
  heat stroke
exertional, 710
heat syncope, 714
miliaria rubra, 713
prevention of, 710–712
  fluid and electrolyte replacement in, 711–712
  recognition of, 712
  sunburn, 713
  treatment of, 713
Heat stress
  environmental
    measurement of, 708–709
Heat stroke
  exertional, 710
  pathophysiology of, 710
Heat syncope, 714
Helminth(s)
  TD due to, 694
Helminth infections
  eosinophilia due to, 788
Hematology tests
  in travelers with tropical diseases, 805
Hepatitis
  A
    vaccine for
      recommended for risk during travel, 602–603
      in VFRs
        risk factors for, 627
  B
    vaccine for
      recommended for risk during travel, 603
High-altitude cerebral edema (HACE), 719–720
High-altitude pulmonary edema (HAPE), 720
Histopathology
  for tropical infections diagnosis
    lab-on-a-chip, 817
    loop-mediated isothermal amplification, 816
    mass spectrometry, 817
    microarrays, 817
    microelectromechanical systems, 817
    microfluidics, 817
    nucleic-acid amplification techniques, 815–816
    nucleic-acid sequence–based amplification, 816
    probe amplification, 816–817
    rapid diagnostic tests, 815
    rolling circle amplification, 816
    signal amplification, 817
    target amplification methods, 815
    transcription-mediated amplification, 816
HIV infection
  antiretroviral therapy for
    immune reconstitution under, 619
HIV (continued)
travelers with malaria prevention in, 652
Human African trypanosomiasis serology for, 813
Hydatid disease serology for, 813
Hydroxychloroquine in malaria prevention in travelers, 642
Hypothermia accidental, 714–715

I
Icaridin in insect bite prevention, 666
Immigrants eosinophilia in rates and associations of, 783
Immune response modulation of antibodies in, 616–617 mounting effective clonal proliferation as central event in, 610–611 normal, 610–611
Immunocompromised travelers travel-associated morbidity in, 799
Immunosuppressed traveler, 609–624 age-related involution of thymus in, 617–619 practical approach to, 619–621
Immunosuppression described, 609–610
Immunosuppressive drugs how they work, 611–617 destroy antibodies that deplete lymphocytes or interfere with cell function, 615–616 destroy dividing cells, 614–615 inhibit intracellular signal transduction from antigen-recognizing T-cell receptor, 613–614 reduce numbers, 611–617 in rabies prevention, 746
Impregnated clothing in insect bite prevention, 667–668
Infectious diseases in mass gatherings, 725–737. See also Mass gatherings
Influenza in mass gatherings vaccine for, 734 pandemic in mass gatherings detection of, 728 vaccine for, 596–599
Insect(s). See also specific insect and Insect bites
   biting by
      mechanism of, 664
Insect bites
   described, 655–664
   prevention of, 655–673
      coils in, 668–669
      impregnated clothing in, 667–668
      mosquito nets in, 668
      myths related to
         debunking of, 669
      spatial repellents in, 668–669
      topical or skin repellents in, 664–667
      vaporizers in, 668–669
   travel-associated
      reactions to, 676–677
International travel
   morbidity during, 794–796
International travelers
   risk factors facing
      vaccines recommended for, 597, 602–606
      vaccines required for entry into destination country, 600–602
IR3535
   in insect bite prevention, 667

J
Japanese encephalitis
   vaccine for
      recommended for risk during travel, 603–604
Jaundice
   causes of, 755–757
      parasitic, 755, 758–760
Jellyfish stings, 684

L
Lab-on-a-chip
   for tropical infections diagnosis, 817
Larva migrans
   visceral
      jaundice due to, 760
Leeches, 685
Leishmaniasis
   serology for, 813
   visceral
      jaundice due to, 758
      in travelers, 765–766
Liver abscess
   amebic
      jaundice due to, 758
Liver (continued)
in travelers, 764–765
Liver disease parasitic
in travelers, 755–780. See also Parasitic liver disease, in travelers travelers with malaria prevention in, 652 prevalence of, 755
Loop-mediated isothermal amplification for tropical infections diagnosis, 816
Loperamide for TD, 697
Lymph node aspirate or biopsy for tropical infections diagnosis, 809
Lymphocyte(s) depletion of antibodies in, 615–616

M

stand-by emergency treatment for, 648–650
in VFRs
  risk factors for, 626–627
Mass gatherings
  defined, 725
  infection control in, 734
  infectious diseases in, **725–737**
  described, 726–727
  detection of, 727–731
    blood-borne pathogens, 730
    endemic infectious diseases of local importance, 730–731
    food-borne diseases, 729–730
    pandemic influenza, 728
    respiratory tract infections, 728–729
    STDs, 730
    TB, 729
    upper respiratory diseases, 728
  prevention of
    recommendations for, 734
    risk assessment for, 727
    vaccine-preventable, 731–734
Mass spectrometry
  for tropical infections diagnosis, 817
Measles
  in mass gatherings
    vaccine for, 732–733
    vaccine for, 599
Mefloquine
  in malaria prevention in travelers, 642, 646
Meningococcal disease
  in mass gatherings
    vaccine for, 731–732
    vaccine for
      for entry into destination country, 601–602
Methotrexate
  in destroying dividing cells, 614–615
Microarrays
  for tropical infections diagnosis, 817
Microelectromechanical systems
  for tropical infections diagnosis, 817
Microfluidics
  for tropical infections diagnosis, 817
Miliaria rubra, 713
Mites
  described, 682
  travel-associated, 682–686
Mosquito(es)
  behavior, diseases spread by, and prevention of bites by,
    657–659
Mosquito nets
  in insect bite prevention, 668
Muscle cramps
  exercise-associated, 714

Mycophenolate
  in destroying dividing cells, 614–615

Myiasis
  travel-associated, 679–680

N

Neurocysticercosis
  serology for, 814

NFCI, 718

Nucleic-acid amplification techniques
  for tropical infections diagnosis, 815

Nucleic acid sequence–based amplification
  for tropical infections diagnosis, 816

O

Older travelers, 630–632
  travel-associated morbidity in, 799

Organ transplant recipients
  international travel by
    malaria prevention in, 652

P

Pandemic influenza
  in mass gatherings
    detection of, 728

Parasitic liver disease
  in travelers, 755–780
    amebic liver abscess, 764–765
    ascariasis, 772–773
    babesiosis, 763–764
    clonorchiasis/opisthorchiasis, 769–770
    echinococcosis, 770–772
    fascioliasis, 768–769
    malaria, 761–763
    prevalence of, 755
    schistosomiasis, 767–768
    visceral larva migrans/toxocariasis, 773–774

PEP. See Postexposure prophylaxis (PEP)

Pericardial effusion aspirate
  for tropical infections diagnosis, 809

Pertussis
  in mass gatherings
    vaccine for, 733
    vaccine for, 599

PMD
  in insect bite prevention, 666–667

Polio
  vaccine for, 599–600
Poliomyelitis
  in mass gatherings
    vaccine for, 733
Postexposure prophylaxis (PEP)
  for rabies, 745–746
Preexposure prophylaxis (PrEP)
  in rabies prevention, 747
Pregnant travelers, 628–629
  general risks for, 628–629
  immunization for, 629
  malaria prevention in, 651
PrEP. See Preexposure prophylaxis (PrEP)
Pretravel health counseling
  for VFRs, 627–628
Primaquine
  in malaria prevention in travelers, 643, 647
Probe amplification
  for tropical infections diagnosis, 816–817
Protozoans
  TD due to, 694
Pulmonary edema
  high-altitude, 720

R
Rabies, 739–753
  cause of, 739–740
  clinical signs and symptoms of, 743
  described, 739–740
  diagnosis of, 743–744
  epidemiology of, 740–742
  management of, 744–746
    acute measures in, 746
    immunosuppressive agents in, 746
    PEP in, 745–746
  pathology of, 743
  prevention of, 745–749
    PrEP in, 747
    in travelers, 748–749
    vaccines in, 604, 745–746
  reservoir for, 742–743
  vaccine for
    recommended for risk during travel, 604, 745–746
Rapid diagnostic tests
  for tropical infections diagnosis, 815
Renal disease
  travelers with
    malaria prevention in, 652
Repellent(s)
  spatial
    in insect bite prevention, 668–669
Repellent(s) (continued)
  topical or skin
    in insect bite prevention, 664–667
Respiratory samples
  for tropical infections diagnosis, 806
Respiratory tract infections
  in mass gatherings
    detection of, 728–729
Rifaximin
  for TD, 698
Rolling circle amplification
  for tropical infections diagnosis, 816

S
Sandflies
  behavior, diseases spread by, and prevention of bites by, 660
Scabies, 682–683
Schistosomiasis
  jaundice due to, 759
  serology for, 814
  in travelers, 767–768
Scorpion stings, 685–686
Serology
  for tropical infections diagnosis, 810–815
    bacterial serology, 811–812
    fungal serology, 812
    parasite serology, 812–815
    viral serology, 810–811
Sexually transmitted diseases (STDs)
  in mass gatherings
    detection of, 730
Signal amplification
  for tropical infections diagnosis, 817
Sirolimus
  in inhibition of intracellular signal transduction from antigen-recognizing T-cell receptor,
    613–614
Skin diseases
  travel-associated, 675–689
    described, 675–676
    generalized disorders, 686–688
      arboviral infection, 686–687
      spotted fevers, 687–688
    laboratory investigations and diagnosis of, 804
    localized disorders, 676–686
      abscesses, 678–679
      insect bite reactions, 676–677
      mites, 682–686
      myiasis, 679–680
      tick bites, 681–682
      tsetse fly bites, 678
      tungiasis, 680–681
Skin samples
   for tropical infections diagnosis, 808
Snakebites, 685
Soft ticks
   behavior, diseases spread by, and prevention of bites by, 663
Spatial repellents
   in insect bite prevention, 668–669
Specimens
   for tropical infections diagnosis, 805–809
      blood specimens, 805–806
      bone marrow biopsy, 809
      CNS samples, 807
      gastrointestinal samples, 807–808
      lymph node aspirate or biopsy, 809
      pericardial effusion aspirate, 809
      respiratory samples, 806
      skin samples, 808
      urine samples, 806–807
Spotted fevers
   travel-associated, 687–688
STDs. See Sexually transmitted diseases (STDs)
Stegomyia mosquitoes
   behavior, diseases spread by, and prevention of bites by, 658
Sting(s)
   scorpion, 685–686
Stress
   heat
      environmental
         measurement of, 708–709
Strongyloides spp.
   serology for, 814
Sunburn, 713
Syncope
   heat, 714

T
Tacrolimus
   in inhibition of intracellular signal transduction from antigen-recognizing T-cell receptor, 613–614
Target amplification methods
   for tropical infections diagnosis, 815
TB. See Tuberculosis (TB)
TBE. See Tick-borne encephalitis (TBE)
TD. See Traveler’s diarrhea (TD)
Tetanus
   vaccine for, 600
Thermoregulation, 709
Thymus
   age-related involution of, 617–619
Tick(s)
   behavior, diseases spread by, and prevention of bites by, 663
Tick bites
  travel-associated, 681–682
Tick-borne encephalitis (TBE)
  vaccine for
    recommended for risk during travel, 604–605
Toxocariasis
  serology for, 814
  VLM and
    in travelers, 773–774
Toxoplasmosis
  serology for, 814
Traffic crashes
  morbidity in travelers related to, 797
Transcription-mediated amplification
  for tropical infections diagnosis, 816
Transplantation
  allogeneic hematopoietic cell
    age-related involution of thymus and bone marrow results in, 617–619
Trauma
  morbidity in travelers related to, 797
Travel
  purpose of, 794
  trends in, 792–794
    age as factor in, 794
    global, 792–793
    length of stay, 794
    purpose of travel, 794
    UK, 793
Travel clinic consultation, 575–593
  conceptions of, 578–582
  described, 575–576
  effectiveness of
    framework for, 585–589
  expected outcomes of, 576–578
  future challenges related to, 589–590
  uptake of medical advice from
    factors affecting, 583–585
Travel industry
  described, 791
Travel risk assessment, 575–593
  attitudes toward, 582–583
  conceptions of, 578–582
  described, 575–576
  expected outcomes of, 576–578
  future challenges related to, 589–590
Travel risk prevention
  attitudes toward, 582–583
Travel-associated morbidity
  health-related problems, 798–799
  during international travel, 794–796
  malaria and, 797–798
patterns of
- travel trends and, 791–802
preexisting morbidity, 796–797
- traffic crashes, 797
- trauma, 797
- risk groups, 799–800
yellow fever and, 798
Travel-associated skin diseases, 675–689. See also Skin diseases, travel-associated Traveler(s)
children, 628–630
diarrhea in, 691–706. See also Traveler’s diarrhea (TD)
eosinophilia in
- rates and associations of, 783
immunocompromised
- travel-associated morbidity in, 799
immunosuppressed, 609–624. See also Immunosuppressed traveler
insect bites in
- prevention of, 655–673. See also Insect bites
malaria in
- prevention of, 637–654. See also Malaria, in travelers
older, 630–632
parasitic liver disease in, 755–780. See also Parasitic liver disease, in travelers
pregnant, 628–629. See also Pregnant travelers
rabies prevention in, 748–749
returning
- eosinophilia in, 781–789. See also Eosinophilia
tropical diseases in
- laboratory investigations and diagnosis of, 803–818. See also Tropical diseases, in travelers, laboratory investigations and diagnosis of
VFRs, 625–635. See also Visiting friends and relatives (VFRs)
vulnerable, 625–635. See also Vulnerable travelers
Traveler’s diarrhea (TD), 691–706
causes of, 692–694
- bacterial pathogens, 693–694
- helminths, 694
- protozoans, 694
- viral pathogens, 694
clinical picture of, 694–695
diagnosis of, 695–696
epidemiology of, 691–692
laboratory investigations and diagnosis of, 804
prevalence of, 691
prevention of, 699–701
- antibiotics in, 699–700
- food hygiene measures in, 699
- nonantibiotic agents in, 699–700
- vaccines in, 700–701
risk factors for
- travel-related, 692
- traveler-related, 692
treatment of, 695–699
Traveler’s (continued)
   antibacterial drugs in, 697–698
   adverse effects of, 698–699
   antisecretory drugs in, 696–697
   duration of, 698
   fluid and electrolytes in, 696
   symptomatic, 696–697
Triatomine bugs
   behavior, diseases spread by, and prevention of bites by, 662
Trichinosis
   serology for, 815
Tropical diseases
   in travelers
      laboratory investigations and diagnosis of, 803–818
         biochemistry, 805
         blood cultures for bacteria or fungi, 809
         future directions in, 817–818
         hematology, 805
         histopathology, 815–817. See also Histopathology, for tropical infections diagnosis
         microscopy for microfilariae, 810
         microscopy of blood films, 810
         serology, 810–815. See also Serology, for tropical infections diagnosis
         specimens, 805–809. See also Specimens, for tropical infections diagnosis
         strategy for, 804
Trypanosomiasis
   American
      serology for, 814
   Human African
      serology for, 813
Tsetse flies
   behavior, diseases spread by, and prevention of bites by, 662
Tsetse fly bites
   travel-associated, 678
Tuberculosis (TB)
   in mass gatherings
      transmission of, 729
   vaccine for
      recommended for risk during travel, 606
   in VFRs
      risk factors for, 627
Tungiasis
   travel-associated, 680–681
Typhoid
   vaccine for
      recommended for risk during travel, 605

U

United Kingdom (UK)
   travel trends in, 793
Upper respiratory diseases
  in mass gatherings
detection of, 728
Urine samples
  for tropical infections diagnosis, 806–807

V
Vaccine(s)
  for diphtheria, 596
diseases prevented by, 595–608. See also specific diseases and Vaccine-preventable diseases
for entry into destination country, 600–602
  for meningococcal disease, 601–602
  for yellow fever, 600–601
in infectious disease prevention in mass gatherings, 731–734
for measles, 596–599
as part of routine health care, 596–600
for pertussis, 599
for polio, 599–600
for pregnant travelers, 629
in rabies prevention
  postexposure, 745–746
  during travel, 604
recommended for risk during travel, 602–606
  for cholera, 602
  for hepatitis A, 602–603
  for hepatitis B, 603
  for Japanese encephalitis, 603–604
  for rabies, 604
  recent advances in, 598
  for TB, 606
  for TBE, 604–605
  for TD, 700–701
  for typhoid, 605
  for tetanus, 600
Vaccine-preventable diseases, 595–608
described, 595–596
prophylaxis of, 595–608. See also specific diseases and Vaccine(s)
Vaporizers
  in insect bite prevention, 668–669
VFRs. See Visiting friends and relatives (VFRs)
Visceral larva migrans (VLM)
  jaundice due to, 760
Visceral larva migrans (VLM)/toxocariasis
  in travelers, 773–774
Visceral leishmaniasis
  jaundice due to, 758
  in travelers, 765–766
Visiting friends and relatives (VFRs), 625–635
  children, 628–630
Visiting (continued)
  defined, 626
  described, 625–626
  older travelers, 630–632
  pregnant travelers, 628–629
  pretravel health counseling for, 627–628
  travel-associated morbidity in, 799–800
  travel-associated risks for, 626
    preventive strategies, 627–628
VLM. See Visceral larva migrans (VLM)
Vulnerable travelers, 625–635

Y
Yellow fever
  travel-associated morbidity related to, 798
  vaccine for
    for entry into destination country, 600–601

Z
Zaldaride maleate
  for TD, 697